||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Verona Pharma Share Discussion Threads
Showing 12526 to 12549 of 12550 messages
|Friday 02 December, 2016
Relvar Ellipta approved in Japan for COPD
RNS Number : 7952Q
02 December 2016|
|I hope the US listing goes somewhat better than it did for Motif Bio (MTFB), which was a disaster as far as the share price was concerned|
|Got to think that the US valuation will be a much higher one than a UK centric one -based on its potential. For various reasons many US funds prefer to buy US listed.
Currency might be one factor.|
|Cracking RNS, onwards and upwards....everything moving into place nicely!|
|surely this shows that the team think they have a great product
why wold you do this with the costs involved if it was to fail its clinicals ?
|RNS - Looking to float in the US next year.|
|Chippenham, UK - 22 November 2016: Vectura Group plc (LSE: VEC) ("Vectura", "the Group"), an industry-leading inhaled airways disease focused business, today announces that it has signed a US development and license agreement with Hikma Pharmaceuticals PLC ("Hikma") (through its wholly-owned subsidiary, West-Ward Pharmaceuticals) for Vectura's VR730 product. VR730 is a generic long acting beta-agonist (LABA) for the treatment of Asthma and COPD delivered using Vectura's proprietary dry powder inhalation technology and device. According to IMS, US sales of inhaled DPI and pMDI LABAs were approximately $150 million in 20151.|
|>>thanks Vas et al
Another thought worth mentioning is that they are unlikely to get an Asthma indication for a product containing vilanterol (only COPD) as FDA really do have it in for LABAs for the treatment of Asthma.|
|GSK are filing for a '3-in-1' 'once per day' dry powder cortisone based medicine for those patients who need multiple therapies.
1 Side effects of fluticasone furoate - http://www.rxwiki.com/fluticasone-furoate
2 Side effects of umeclidinium - http://www.incruse.com/risks-and-side-effects.html
3 Side effects of vilanterol - http://www.everydayhealth.com/drugs/fluticasone-vilanterol
Such a combination therapy tells me that we really do need a new range of non-cortisone based medicines with a much better side effects profile - thus the potential of RPL554 to become a novel 'first in class' medicine.|
|Glaxo have accelerated timing for their triple therapy for COPD in US from 2018 to end 2016.|
|From the USA..
|This news from the NA Cystic Fibrosis Conference in Orlando has been on the Radio 4 Today programme this morning - http://www.bbc.co.uk/news/health-37795460
Note that due to very high costs (£100,000 per patient per annum) it is not available on the NHS, and it only seems to be effective for around half CF patients.
So it's worth pointing out again the relevant paragraph from Verona's RNS on Monday in relation to today's news from Orlando -
'In clinical trials, RPL554 has been observed to be an
effective bronchodilator and to have anti-inflammatory properties in vitro as
well as in a standard inhaled lipopolysaccharide challenge study in healthy
volunteers. In these studies, the drug candidate has been well tolerated.
Pre-clinical data to date has suggested that RPL554 is also a stimulator of the
CFTR, which is dysfunctional in cells of cystic fibrosis patients. Based on
these observed favorable properties, the Company believes RPL554 may improve
mucociliary clearance (reduce phlegm in the airways), reduce symptoms of
chronic inflammation and ease breathing.'
Bearing in mind that RPL554 may also be a stimulator of the CFTR in similar fashion to lumicaftor/vacaftor, and the NHS's current position with regards to very high costs per treatment per patient per annum, if Verona can show further positive data then surely they will be knocking on an open door to get orphan drug status for CF - especially with the current backing of the CF Trust.
We also still await to hear if anything 'new' has been announced in Orlando as per Monday's RNS.|
|...spoke too soon!!|
|...and an encouraging bounce off the 3.75p line too..|
|Agreed Tim. No doubt the award was made on the basis of new positive data. I would very much like to see the details of that data to be made available over the next few days -
'New pre-clinical data of RPL554 in CF will be available from 26 October 2016
and presented during two poster sessions on 27 and 28 October 2016 at the
Annual North American Cystic Fibrosis Conference in Orlando, Florida.'|
|New CF trial:
|When is the Nasdaq quoting taking place?tia|
|Well one thing is certain and that's that US fund managers would give a much higher valuation to this and may be happier to buy a NASDAQ quoted vehicle.|
|Well, what's going on all of a sudden...?|
|I think you may be right. I understand that the proposed NASDAQ listing will be some sort of Depository Interest like an ADR or ADS so the Xetra listing may no longer be needed as it would an extra layer of complexity when creating or splitting the ADRs or ADSs. More sensible to have one listing of the GBP shares on the LSE and one for the US ADRs or ADSs only.|
|Maybe they have decided it's not worth having 3 different listings in future, so they are cleaning up before announcing a new listing on Nasdaq.|
|You are making the assumption that the share price rise is linked to the RNS. It might well be.
Perhaps cost savings? Clearly the company has decided that that listing had no tangible benefits. Any other views???|
|...not sure why this move is being seen as so positive?|